Swedish Orphan Biovitrum

Sobi is a pharmaceutical company specialized in rare diseases. Our aim is to continue to develop rare disease treatments and to create access to those for patients.

We will continue to build on our strong position that covers the entire value chain for treatment of rare diseases in EMENAR and North America. Sobi offers an integrated process, from in-house research and development in protein characterisation, biologics manufacturing and industrialisation, to commercialisation of products for rare diseases. Partnering with stakeholders and facilitating effective and timely rare-disease therapy development, including an extensive and robust distribution network, creates unique opportunities for us to add value to the rare-disease field.

Health policy, primarily those related with rare disease policy and access to medicines

1

0.25

None declared

Ms Ana Palma (Global HTA & Patient Access Lead BNL)

Ms Carin Dahlquist (Associate General Counsel)

II - In-house lobbyists and trade/business/professional associations

Companies & groups